HER2-Positive Gastric Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

HER2-positive gastric cancer refers to a specific subtype of stomach cancer that is characterized by overexpression of the human epidermal growth factor receptor 2 (HER2) protein. HER2 is a gene that plays a role in normal cell growth, but when overexpressed in cancer cells, it can promote the growth and spread of cancer. In gastric cancer, HER2 overexpression is found in a subset of tumors, estimated to be around 10-20% of cases. The overexpression of HER2 is typically assessed through immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) testing on a tissue biopsy taken during diagnostic procedures. The significance of HER2 overexpression in gastric cancer is that it can be a predictive biomarker for targeted therapy. Trastuzumab (Herceptin) is a monoclonal antibody targeting the HER2 protein. It is effective in the treatment of HER2-positive gastric cancer, both in advanced and early-stage disease. Patients with HER2-positive gastric cancer may receive a combination of chemotherapy and trastuzumab. The addition of trastuzumab to chemotherapy has been associated with improved survival outcomes in HER2-positive gastric cancer patients. The prevalence of HER2-positive gastric cancer is 22%, with HER2 overexpression in gastric cancer varying between 6% and 30%, depending on the primary tumor’s location. Higher rates of HER2 positivity are observed in tumors located at the gastroesophageal junction (GEJ) or stomach cardia than those originating more distally in the stomach.

Thelansis’s “HER2-Positive Gastric Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HER2-Positive Gastric Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of HER2-Positive Gastric Cancer across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

HER2-Positive Gastric Cancer Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: HER2-Positive Gastric Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033